DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured ...

Eli Lilly has an accrual ratio of 0.25 for the year to December 2024. We can therefore deduce that its free cash flow fell well short of covering its statutory profit. To wit, it produced free ...

Eli Lilly plans four new U.S. manufacturing sites, expanding domestic production and reshoring pharmaceutical ingredient manufacturing. $50B expansion since 2020 includes four sites, creating over ...

Imagine Entertainment and MACRO Partner With Eli Lilly and Company to Bolster Film and TV Representation of Health Conditions Katcy Stephan Thu, February 27, 2025 at 6:00 PM UTC ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...